Related Experiment Video
Updated: Nov 30, 2025

Author Spotlight: Novel Intraperitoneal Injection Method for Zebrafish Cardiotoxicity Models
Published on: March 29, 2024
Adriamycin does not damage podocytes of zebrafish larvae
Maximilian Schindler1, Antje Blumenthal1, Marcus Johannes Moeller2
1Department of Anatomy and Cell Biology, University Medicine Greifswald, Greifswald, Germany.
Abstract:
Podocytes are highly specialized epithelial cells that are essential for an intact glomerular filtration barrier in the kidney. Several glomerular diseases like focal segmental glomerulosclerosis (FSGS) are initially due to podocyte injury and loss. Since causative treatments for FSGS are not available until today, drug screening is of great relevance. In order to test a high number of drugs, FSGS needs to be reliably induced in a suitable animal model. The zebrafish larva is an ideal model for kidney research due to the vast amount of offsprings, the rapid development of a simple kidney and a remarkable homology to the mammalian glomerulus. Zebrafish larvae possess a size-selective glomerular filtration barrier at 4 days post fertilization including podocytes with interdigitating foot processes that are connected by a slit membrane. Adriamycin is an anthracycline which is often used in mice and rats to induce a FSGS-like phenotype. In this study, we aimed to induce a similar phenotype to zebrafish larvae by adding adriamycin to the tank water in different concentrations. Surprisingly, zebrafish larvae did not develop glomerular injury and displayed an intact filtration barrier after treatment with adriamycin. This was shown by (immuno-) histology, our filtration assay, in vivo imaging by 2-photon microcopy, RT-(q)PCR as well as transmission electron microscopy. To summarize, adriamycin is unable to induce a podocyte-related damage in zebrafish larvae and therefore major effort must be made to establish FSGS in zebrafish larvae to identify effective drugs by screenings.
Insights
Adriamycin does not induce kidney damage in zebrafish larvae, hindering efforts to screen for focal segmental glomerulosclerosis (FSGS) drugs. Further research is needed to establish a reliable FSGS model in zebrafish for drug discovery.
Area of Science:
- Nephrology
- Developmental Biology
- Toxicology
Background:
- Podocytes are crucial for kidney filtration; injury leads to diseases like focal segmental glomerulosclerosis (FSGS).
- Effective treatments for FSGS are lacking, necessitating drug screening.
- Zebrafish larvae offer a promising model for kidney research due to their homology and rapid development.
Purpose of the Study:
- To establish a zebrafish model for inducing FSGS-like kidney injury using adriamycin.
- To evaluate adriamycin's efficacy in causing podocyte damage and glomerular dysfunction in zebrafish larvae.
Main Methods:
- Zebrafish larvae were exposed to varying concentrations of adriamycin.
- Kidney integrity was assessed using histology, filtration assays, 2-photon microscopy, RT-(q)PCR, and transmission electron microscopy.
Main Results:
- Adriamycin treatment did not cause glomerular injury or filtration barrier defects in zebrafish larvae.
- Histological and imaging analyses confirmed intact podocytes and filtration barriers post-treatment.
Conclusions:
- Adriamycin is ineffective in inducing podocyte damage or FSGS-like phenotypes in zebrafish larvae.
- Developing a reliable method to induce FSGS in zebrafish is essential for future drug screening and discovery.

